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SHORT COMMUNICATION
Electroporation-mediated delivery of a naked DNA
plasmid expressing VEGF to the porcine heart
enhances protein expression
WG Marshall Jr1,5, BA Boone1, JD Burgos1, SI Gografe2,6, MK Baldwin2, ML Danielson2, MJ Larson2,
DR Caretto2, Y Cruz3, B Ferraro3, LC Heller3,7, KE Ugen3, MJ Jaroszeski4 and R Heller3,5,7
1Department of Surgery, University of South Florida, Tampa, FL, USA; 2Department of Comparative Medicine, University of South
Florida, Tampa, FL, USA; 3Department of Molecular Medicine, University of South Florida, Tampa, FL, USA and 4Department
of Chemical Engineering, University of South Florida, Tampa, FL, USA
Gene therapy is an attractive method for the treatment of
cardiovascular disease. However, using current strategies,
induction of gene expression at therapeutic levels is often
inefficient. In this study, we show a novel electroporation (EP)
method to enhance the delivery of a plasmid expressing an
angiogenic growth factor (vascular endothelial growth factor,
VEGF), which is a molecule previously documented to
stimulate revascularization in coronary artery disease. DNA
expression plasmids were delivered in vivo to the porcine heart
with or without coadministered EP to determine the potential
effect of electrically mediated delivery. The results showed that
plasmid delivery through EP significantly increased cardiac
expression of VEGF compared with injection of plasmid
alone. This is the first report showing successful intracardiac
delivery, through in vivo EP, of a protein expressing plasmid
in a large animal.
Gene Therapy (2010) 17, 419–423; doi:10.1038/gt.2009.153;
published online 3 December 2009
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Advances in the treatment of coronary artery disease
(CAD) have been attained through interventions, such
as angioplasty and coronary artery bypass surgery.1
However, some CADs are not amenable to these
interventions, indicating that development of other
therapies is required. One such therapeutic strategy is
the induction of revascularization through targeted gene
therapy.2–6 Vascular endothelial growth factor (VEGF) is
an angiogenic protein used to stimulate angiogenesis in
models of CAD and, as such, has been evaluated as a
therapeutic target. Genes encoding VEGF isoforms can
potentially circumvent many of the obstacles presented
by restenosis and other cardiovascular pathologies
through the stimulation of potentially therapeutic col-
lateral vessel formation.
Direct naked/nonviral DNA plasmid injection and
adenoviral-mediated gene transfer6,7 have shown promise
for treating CAD. In addition to providing symptomatic
relief during ischemia, studies indicated that VEGF
stimulates collateral vessel formation even in nonischemic
hearts.8 However, some drawbacks exist for adenoviral-
mediated and nonviral naked DNA direct injection gene
therapy methods. For example, nonviral DNA delivery
has been shown to often mediate low and short-term gene
expression, whereas adenoviral vectors have some toxicity
concerns. Toxicity issues for the adenoviral-based vectors
include the generation of ‘memory’ immune responses,
after delivery of the vector, against the adenoviral vector
backbone. This is likely due to the previous exposure to a
number of ‘natural’ adenoviruses during life.
The nonviral naked DNA approach, although some-
what inefficient, deserves further scrutiny because of its,
to date, more favorable patient safety profile. In fact,
numerous subjects have been ‘vaccinated’ with antigens
expressed from naked DNA plasmids without the
development of significant adverse events. Several
nonviral methods have been developed in an attempt
to enhance delivery of DNA and have been the focus of
several reviews.9–12 Both chemical and physical techni-
ques including liposomes,13–15 particle bombardment16–18
and hydrodynamic delivery19,20 have been described and
used to increase the efficiency of tissue DNA uptake.
Another physical delivery method to circumvent
problems of low protein expression associated with
naked viral-based DNA plasmids is the delivery of
genes through in vivo electroporation (EP). The demon-
stration that electric fields can be safely and effectively
applied in vivo to deliver small molecules21 and the
widespread use of EP to deliver plasmid DNA to cells
in vitro provided a foundation for the use of EP to deliver
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plasmid DNA in vivo. EP is a simple and direct, in vivo
method used to deliver genes for therapy. The use
of electric pulses for the in vivo delivery of plasmid
DNA has been steadily increasing. Preliminary results
indicate that therapeutic plasmid DNA delivery could
potentially achieve similar success to conventional drug
delivery. Multiple studies have shown the feasibility of
this approach, primarily in skin, skeletal muscle and
tumors.22–25
Importantly, the EP delivery method has recently been
successfully evaluated in a clinical trial in which
an interleukin-12-expressing plasmid was delivered to
patients with metastatic melanoma.26 A second clinical
trial delivered a cancer vaccine to muscle.27 In terms of
the application of EP-mediated delivery of therapies
against CAD, two studies have reported using electric
pulses to transfer genes to the heart. Both of these studies
used explanted/ex vivo heart samples collected either
from mice or from embryonic chicks.18,28
Therefore, it was hypothesized that EP could deliver
plasmid DNA to the heart for the potential treatment of
CAD. The goal of the study presented here was to
establish a safe and potentially therapeutic EP-based
plasmid DNA delivery to the heart in a large animal
model, which could potentially be translated to human
medicine. The pig is a useful model for these studies
because of similarities between pigs and humans in
terms of cardiac and coronary artery anatomy, as well as
physiology. This proof-of-concept brief communication
describes the successful novel delivery of expression
plasmids to the porcine heart.
The initial experiment involved injection of a plasmid-
encoding luciferase, pLuc (gWizLuc, Gene Therapy
Systems, San Diego, CA, USA), followed by the admin-
istration of EP. This in four pigs with injection of the
plasmid made in two sites marked with polypropylene
sutures in the anterior left ventricular wall in a line
1.5 cm lateral to the left anterior descending coronary
artery B2 cm apart. A second set of injection sites was
made 2 cm lateral to the initial line with this line of sites
now in the lateral ventricular wall supplied by the left
circumflex artery. The sites were again 2 cm apart. A total
of four injection sites were made in each heart. Three
sites received EP delivered to individual sites after
each injection. One site received plasmid injection
without EP and a biopsy site was taken in the far lateral
ventricular wall without plasmid injection or EP. This
same delivery technique was used in each group of
pigs described below.
These pulses were administered at a rate of 8 per
second and were not synchronized with the heart
rhythm (ASYNC). The pLuc delivery experiments were
carried out to determine which of the EP parameters
resulted in the highest levels of gene expression. The
rationale for using ASYNC pulses was to assess whether
such a delivery could be applied safely and whether it
was effective in enhancing gene expression. Forty-eight
hours after pLuc and EP administration, the myocardial
expression of luciferase was quantified in cardiac biopsy
samples (collected with a 6-mm biopsy punch) using
commercial firefly luciferase (Sigma-Aldrich Chemical,
St Louis, MO, USA). These data are shown in Figure 1a.
There was a significant increase in expression when
pLUC was delivered with EP compared with injection
alone. The highest expression was obtained using an
applied field strength of 100 V cm1 and a pulse width of
250 ms. These optimal EP parameters (that is, 250 ms of
pulse width and 100V cm1 of applied field strength)
were then subsequently used to deliver pVEGF. Two or
seven days after the delivery of pVEGF to pig hearts (two
injection and EP sites, one injection only site and one no-
treatment site), a myocardial tissue punch (6 mm) of the
treated sites was excised and the VEGF expression in the
samples was measured (expressed as picogram of VEGF
per gram tissue) using a commercial Quantikine human
VEGF quantitative sandwich ELISA (enzyme-linked
immunosorbent assay) kit (R&D Systems, Minneapolis,
MN, USA). In these experiments, the VEGF expression
was significantly higher at 2 but not at 7 days after
treatment compared with the pVEGF treatment without
EP (Figure 1b). In summary, for these initial EP delivery
experiments, EP increased expression by 25- and 5-fold
for luciferase and VEGF, respectively. Although both
proteins were expressed from vectors containing the
CMV promoter, differences in protein-fold increase
levels and duration of expression were observed. Several
possible variables may have produced this difference.
Different CMV promoter/enhancers do not necessarily
produce identical expression. Other plasmid structural
elements, for example, the polyadenylation signal,
may affect expression. Luciferase was detected using
a functional assay, whereas VEGF was detected using an
antibody assay. Finally, the proteins expressed may differ
in half-life. Although the luciferase protein half-life in
mammalian cell culture is 3 h,29 the half-life of VEGF
in vivo has been measured at 6 and 50 min.30,31
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Although the primary objective of increasing protein
expression was obtained, it was observed that ASYNC
pulses resulted in ventricular fibrillation in all the pigs
Although most of the pigs were successfully defibril-
lated, it was reasoned that the development of a
synchronous (SYNC) EP pulse delivery method, in
which the pulses could be delivered in synchrony with
the normal heart rhythm would circumvent this pro-
blem. Therefore, in a subsequent set of plasmid injection
experiments, electrical pulses were delivered to the heart
synchronously with the QRS complex determined using
a surface electrocardiogram. Importantly, the initial
experiments indicated that delivering SYNC pulses
eliminated ventricular fibrillation.
Synchronous electrical pulses, delivered during the
absolute refractory period of the cardiac electrical cycle,
have long been known to have minimal risk of causing
electrical fibrillation; for example, as used to treat atrial
arrhythmias. Hojman et al.,32 have shown that EP induces
changes in Na+ and K+ fluxes, and in Ca2+ content in the
skeletal muscle with larger changes when DNA is
present with EP. These effects may also be present in
the cardiac muscle and in treatment of the heart, but
have not been definitely shown. The larger and more
determinant effect is the timing of the pulse delivery
within the absolute refractory period of the cardiac cycle.
To determine the SYNC EP conditions that result in
maximal expression, experiments were conducted again
in six pigs with pLuc injection plus EP using six injection
and EP sites, two injection-only sites and two no-
treatment sites in each heart (half were evaluated for
expression and the other half underwent histological
evaluation). In these experiments, it was determined that
the pulse length was required to be shortened to be
synchronized with the QRS wave. In the experiment
summarized in Figure 2a, expression of luciferase was
measured in the porcine hearts either 2 or 7 days after
treatment. In this experiment, the highest level of
expression was 10 000- and 15-fold higher at day 2 or
7, respectively, compared with pLuc treatment without
EP. Interestingly, using different pulsing conditions
resulted in not only different peak levels of luciferase
expression but also in different expression kinetics. Peak
short-term expression (2 days) that was significantly
higher than injection alone was obtained using
an applied field strength of 80 V cm1 and a pulse width
of 20 ms. The expression was no longer significantly
higher than injection alone by 7 days. In contrast, when
pLUC was delivered with an applied field strength of
120 V cm1 and pulse width of 20 ms, peak expression
was delayed to 7 days and was significantly higher. This
suggests the versatility of delivery with EP, as certain
expression patterns can be obtained using different EP
delivery parameters. In experiments in which pVEGF
was delivered (in six pigs using five injection sites and
one no-treatment site in each heart) with SYNC pulses,
the maximal VEGF expression was fivefold higher than
pVEGF injection alone, when measured at a 2-day post-
treatment time point (Figure 2b). No episodes of
ventricular fibrillation were experienced using the SYNC
EP delivery technique. VEGF expression was evaluated
at peak expression (day 2) on the basis of the results
presented in Figure 1b, which showed a decrease in
VEGF expression to background by day 7.
Figure 1 Cardiac expression of luciferase or VEGF following ASYNC EP-mediated delivery of pLuc or pVEGF pLuc (a) or pVEGF (b) were
administered by intracardiac injection followed by ASYNC pulses. Expression for luciferase and VEGF are given as mean pg mg1 and pg g1
cardiac tissue sample ±s.d. respectively. In the figures P+ and P designates with or without plasmid injection whereas E+ and E
designates with or without delivery via EP. Results for luciferase expression represent a mean and s.d. of three sites (four sites for injection
only) and for VEGF the results are a mean and s.d. of six sites. A total of 10 pigs (30–35 kg) were used for these sets of experiments (four for
luciferase and six for VEGF). Multiple sites were utilized on the heart of each animal. Statistical analysis: statistical comparisons for protein
expression were determined between the groups receiving electroporation and P+E (plasmid injection alone) by Student’s unpaired t-test.
For statistical comparisons which included greater than two groups (comparison between experimental groups) the analysis was done by
nonparametric ANOVA. The asterisk symbol (*) indicates significantly elevated expression (Po0.05) compared with control. Plasmids: To
construct pVax1-hVEGF165, a fragment containing hVEGF165 was subcloned from pBLAST49-hVEGFv2.0 (HYPERLINK ‘https://
webmail.odu.edu/owa/www.invivogen.com’ InvivoGen, San Diego, CA, USA) into pVax1 (Invitrogen Corp., Carlsbad, CA, USA), which
contains the CMV promoter and the BGH polyadenylation signal. The plasmid was commercially prepared (Aldevron, Fargo, ND, USA) and
suspended in sterile injectable saline. Endotoxin levels were o0.1 EU/mg plasmid. The pLuc used in the studies was a gWizLuc plasmid
(Aldevron). Anesthesia: animals were anesthetized during DNA injection and electric pulse administration. Pre-anesthetic agents: induction:
Ketamine 10–20 mg kg1 i.m. for immobilization, Atropine 0.02 mg kg1 i.v., Sufentanil 0.015 mg kg1 h1 i.v. followed by 0.007 mg kg1
Sufentanil bolus after 5 min. Maintenance: Sufentanil 0.015–0.030 mg kg1 h1 i.v. infusion supplemented by 0.5–1.0% isoflurane in oxygen
via inhalation (that is, intubation). Monitoring: animals were monitored using EKG monitoring, pulse oximetry (O2 sat), capnography (end-
tidal CO2), and rectal temperature. Medications: antibiotics: Cephalexin 10 mg kg1 i.v. once for antibiotic prophylaxis, Anti-arrhythmic:
Amiodarone 5–10 mg kg1 was injected intravenously just before cardiac manipulation and every 30 min as required with use of Lidocaine
intravenously p.r.n. Surgical procedure: Animals were placed in supine position and on a warming blanket. Steri-drape was used to cover
from neck to mid-abdomen. Incision was made in skin from sterno-manubrial junction to xyphoid using a no. 10 Blade. The subcutaneous
tissue was divided to sternum using electrocautery and then the sternum divided with a stryker oscillating saw. Arrhythmias were treated as
indicated above and the sternum closed with 0 wire and soft tissues closed in layers with absorbable suture. Plasmid injection and
electroporation: plasmid DNA (pLuc or pVEGF) was injected (200 mg in 100 ml of sterile saline) in multiple sites in the left ventricle followed
by EP at specific delivery parameters that varied by field strength and pulse width. EP was administered via an epicardial probe at the
designated parameters. The electric fields were applied using an applicator containing an array of 16 electrodes and a firing sequence of a
series of 2 2 mm squares. Four pulses were fired in each direction (total of 72 pulses for entire array). Internal defibrillation was
administered as needed (10–50 J) in all animals receiving asynchronous EP and the heart allowed to recover for 10–15 min following
restoration of normal sinus rhythm. Location of treatment site(s) were marked with 4–0 prolene suture. Two controls were performed;
plasmid delivery without EP and an untreated control, in which there was neither plasmid injection nor administration of EP. Evaluation: At
2 or 7 days post-operatively, the sternotomy was re-opened. The injection sites were excised with a 6 mm punch and sent for luciferase or
VEGF assays. Luciferase expression was quantified using commercial firefly luciferase (Sigma, St Louis, MO, USA). A sandwich ELISA kit
was used for detection of VEGF. The animals were euthanized with intracardiac-administered potassium chloride. This experimental animal
surgery and treatment protocol was approved by the University of South Florida Institutional Animal Care and Use Committee and all
experiments were performed in accordance with all relevant guidelines and regulations.
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An ability to tailor EP parameters for differential
expression may be useful for optimal results and to
minimize complications in a clinical situation. It is
unclear at this time when the most optimal delivery
periods would be and how long they would persist.
Further study is necessary. The VEGF levels in this study
are higher than in a clinical study by Kastrup et al., but
the levels in this study were myocardial tissue levels,
whereas the clinical study measured serum levels.33,34
No significant increase in serum levels of VEGF were
observed in this study. The regional localization and lack
of systemic increases in VEGF may have significant
advantages in mitigation of complications due to
increased VEGF levels with neovascularization in the
retina in diabetes and neovascularity to support tumor
formation/growth. More study is necessary to define the
optimal target levels of VEGF both in the myocardium
and in the serum, both in experimental and in clinical
situations.
In addition to the assessment of expression, biopsy
samples of the injection/EP sites were also examined
histologically. There was evidence of pericarditis in all
samples. This was an expected sequela of the cardiac
manipulations. Some mild-to-moderate inflammatory
responses were also noted in several samples,
which could not be directly associated with treatment
conditions.
To our knowledge, this is the first report of the
successful delivery of a plasmid expressing a vascular-
ization-modifying protein such as VEGF to the porcine
heart through EP. The expression of VEGF was increased
significantly in tissue surrounding the cardiac injection
site that had received pVEGF plus EP. These studies
indicate a proof-of-concept validation of this method and
provide the impetus for further investigation. These
studies will include safety analysis as an assessment
of potential treatment-associated biological and clinical
effects. Ultimately, these studies will indicate the
potential for this technique and strategy for the treatment
of CAD in humans.
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Figure 2 Cardiac expression of luciferase or VEGF following
SYNC EP-mediated delivery of pLuc or pVEGF. pLuc (a) or pVEGF
(b) was administered by intracardiac injection followed by SYNC
pulses. The electric fields were applied using an applicator
containing four needle electrodes that were 6 mm long and
arranged to form a 5 5 mm square. Four pulses were fired in
two perpendicular directions (total of eight pulses for the entire
array). Expression for luciferase and VEGF are given as mean
pg mg1 and pg g1 cardiac tissue sample±s.d. respectively. In the
figures P+ and P designates with or without plasmid injection
whereas E+ and E designates with or without delivery via EP.
Methods are as described in the legend for Figure 1 except that EP
pulses were synchronized with the heart rhythm. Electroporation
pulses were administered individually just before the peak of the
r wave (within the qrs complex) and completed before the initiation
of the t wave. Results for luciferase expression represent a mean and
s.d. of three sites and for VEGF the results are a mean and s.d. of
four sites except for injection only (five sites) and injection and
electroporation with 20 ms and 120 V cm1 (five sites). A total of 12
pigs (30–35 kg) were used for these experiments (six for luciferase
and six for VEGF). Multiple sites were used on the heart of each
animal. For histological evaluation, four sections were prepared
from each biopsy and stained with hematoxylin and eosin and then
assessed by pathological examination to determine any evidence of
damage as well as immune or inflammatory reactions. Electropora-
tion sites were treated before the non electroporated sites. Statistical
analysis: Statistical comparisons were performed as described in
Figure 1 legend. The asterisk symbol (*) on a column indicates that
the expression for that treatment on day 2 was significantly elevated
(Po0.05) compared with day 2 control. The hash (#) symbol on a
column indicates that the expression for that treatment on day 7 was
significantly elevated (Po0.05) compared with day 7 control.
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